Zoetis Inc. $ZTS Shares Bought by Texas Capital Bank Wealth Management Services Inc

Texas Capital Bank Wealth Management Services Inc raised its position in Zoetis Inc. (NYSE:ZTS) by 124.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 100,046 shares of the company’s stock after buying an additional 55,562 shares during the quarter. Texas Capital Bank Wealth Management Services Inc’s holdings in Zoetis were worth $7,189,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of ZTS. Auxano Advisors LLC raised its position in Zoetis by 23.0% in the 2nd quarter. Auxano Advisors LLC now owns 4,044 shares of the company’s stock valued at $291,000 after purchasing an additional 755 shares during the last quarter. BlackRock Inc. boosted its stake in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. Dunhill Financial LLC grew its position in Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after purchasing an additional 296 shares during the last quarter. Pallas Capital Advisors LLC increased its stake in Zoetis by 83.6% in the second quarter. Pallas Capital Advisors LLC now owns 4,142 shares of the company’s stock valued at $298,000 after purchasing an additional 1,886 shares during the period. Finally, Deutsche Bank AG increased its stake in Zoetis by 5.8% in the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after purchasing an additional 319,709 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 1.5%

ZTS stock opened at $72.71 on Tuesday. Zoetis Inc. has a one year low of $71.00 and a one year high of $160.48. The stock has a market capitalization of $30.05 billion, a PE ratio of 11.98, a price-to-earnings-growth ratio of 1.28 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a fifty day moving average of $76.17 and a 200-day moving average of $98.47.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts expect that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s payout ratio is presently 34.93%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Piper Sandler decreased their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. JPMorgan Chase & Co. reduced their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. BNP Paribas Exane decreased their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Finally, HSBC lowered their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.